NPS Pharmaceuticals is a biopharmaceutical company engaged in bringing orphan products to patients who have rare disorders and few, if any, therapeutic options. The FDA-approved Gattex 0.05 mg/kg/d for subcutaneous injection is the company’s lead product. In addition to its … Continue reading →

Furiex Pharmaceuticals is a drug development collaboration company using innovative clinical development design to accelerate and increase the value of drug development programs, cost-efficiently advancing them through the drug discovery and development process. The company’s drug development programs are designed … Continue reading →

ReNeuron Group is a clinical-stage stem cell leader primarily focused on developing novel stem cell therapies to target areas of important unmet or inadequately met medical need. The company has used its stem cell technologies to develop cell-based therapies for … Continue reading →

Rigel Pharmaceuticals is a clinical-stage drug development company engaged in the discovery and development of novel, small-molecule drugs to treat inflammatory and autoimmune diseases and muscle disorders. The company’s groundbreaking research is focused on intracellular signaling pathways and related targets … Continue reading →

ImmunoCellular Therapeutics is a clinical-stage company focused on the development of immune-based therapies for treating brain and other cancers. The company is conducting a Phase II trial of its lead product candidate ICT-107, which is a dendritic cell-based vaccine targeting … Continue reading →

DiaMedica is a biotechnology company engaged in the development of first-in-class treatments for diabetes. DM-199, the company’s lead compound, is a recombinant human protein for treating both Type 1 and Type 2 diabetes and their related complications. DiaMedica is also … Continue reading →

Advanced Cell Technology is a biotechnology company focused on the application of cellular technology in the field of regenerative medicine. The company specializes in developing cellular therapies to treat diseases and conditions impacting tens of millions of people across the … Continue reading →

Transition Therapeutics is a biopharmaceutical company focused on the development of novel therapeutics for disease indications with large markets. The company’s lead product, ELND005, is a treatment for Alzheimer’s disease and bipolar disorder. Transition additionally has an emerging pipeline of … Continue reading →

Oncolytics Biotech is a biotechnology company engaged in developing oncolytic viruses as potential therapeutics for cancer. Based in Calgary, Canada, the company has a clinical program that includes various human trials, such as a Phase III trial using REOLYSIN, its … Continue reading →

ChemoCentryx is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of orally administered therapeutics targeting the chemokine and chemoattractant systems to treat autoimmune diseases, inflammatory disorders and cancer. The company has generated multiple clinical and preclinical-stage programs … Continue reading →